ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

HER2-Positive Breast Cancer

HER2-Positive Breast Cancer

Using a novel imaging technique, researchers have discovered that differences in HER2 homodimers on breast cancer cells may point toward functional differences, with possible implications for metastasis and drug resistance.

[18F]FDG-PET/CT could predict response in patients with metastatic HER2-positive breast cancer treated with lapatinib plus trastuzumab.

Neoadjuvant TDM-1 was shown to be effective in treating HER2-positive, HR-positive breast cancer compared with trastuzumab, with or without endocrine therapy.

The addition of pertuzumab to trastuzumab and docetaxel offers significant improvement over other options in patients with HER2-positive breast cancer.

A randomized trial failed to show non-inferiority of 6 months of adjuvant trastuzumab compared with the standard 12 months for HER2-positive breast cancer.

MM-302 showed encouraging efficacy results and a manageable safety profile in heavily pretreated HER2-positive metastatic breast cancer patients.

Neoadjuvant chemotherapy is sometimes paired with anthracyclines, such as daunorubicin, doxorubicin, and epirubicin, to treat some types of breast cancer. Because of the success of this regimen for patients with breast cancer--with up to 65% of pathological complete responses (pCR)--this has become a standard of care.

Pages

Subscribe to HER2-Positive Breast Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.